Recombinant MS4A1 (Rituximab Biosimilar) 抗体
-
- 抗原 See all MS4A1 (Rituximab Biosimilar) products
- MS4A1 (Rituximab Biosimilar)
- 抗体类型
- Recombinant Antibody
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This MS4A1 (Rituximab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Rituximab Biosimilar, CD20 Monoclonal Antibody
- 特异性
- The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.
- 产品特性
- Recombinant Humanized IgG1 Monoclonal Antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.
- 克隆位点
- 10F381
- 亚型
- IgG1 kappa
-
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- MS4A1 (Rituximab Biosimilar)
- Abstract
- MS4A1 (Rituximab Biosimilar) 产品
- 别名
- B1 antibody, Bp35 antibody, CD20 antibody, CVID5 antibody, LEU-16 antibody, MS4A2 antibody, S7 antibody, membrane spanning 4-domains A1 antibody, MS4A1 antibody
- 物质类
- Biosimilar
- 背景
-
B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.
Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
-